688 related articles for article (PubMed ID: 27637004)
41. Anti-IL-4/-13 based therapy in asthma.
Walsh GM
Expert Opin Emerg Drugs; 2015 Sep; 20(3):349-52. PubMed ID: 26021492
[TBL] [Abstract][Full Text] [Related]
42. Role of interleukin-13 in asthma.
Corren J
Curr Allergy Asthma Rep; 2013 Oct; 13(5):415-20. PubMed ID: 24026573
[TBL] [Abstract][Full Text] [Related]
43. Commonality of the IL-4/IL-13 pathway in atopic diseases.
Gandhi NA; Pirozzi G; Graham NMH
Expert Rev Clin Immunol; 2017 May; 13(5):425-437. PubMed ID: 28277826
[TBL] [Abstract][Full Text] [Related]
44. The use of biological agents for the treatment of fungal asthma and allergic bronchopulmonary aspergillosis.
Moss RB
Ann N Y Acad Sci; 2012 Dec; 1272():49-57. PubMed ID: 23231714
[TBL] [Abstract][Full Text] [Related]
45. Targeting the interleukin pathway in the treatment of asthma.
Chung KF
Lancet; 2015 Sep; 386(9998):1086-96. PubMed ID: 26383000
[TBL] [Abstract][Full Text] [Related]
46. Anti-interleukin-4 therapy.
Steinke JW
Immunol Allergy Clin North Am; 2004 Nov; 24(4):599-614, vi. PubMed ID: 15474861
[TBL] [Abstract][Full Text] [Related]
47. Emerging interleukin receptor antagonists for the treatment of asthma.
Al Efraij K; FitzGerald JM
Expert Opin Emerg Drugs; 2017 Sep; 22(3):275-283. PubMed ID: 28832218
[TBL] [Abstract][Full Text] [Related]
48. New anti-asthma therapies: suppression of the effect of interleukin (IL)-4 and IL-5.
Kips JC; Tournoy KG; Pauwels RA
Eur Respir J; 2001 Mar; 17(3):499-506. PubMed ID: 11405532
[TBL] [Abstract][Full Text] [Related]
49. Molecular Targets for Biological Therapies of Severe Asthma.
Pelaia C; Crimi C; Vatrella A; Tinello C; Terracciano R; Pelaia G
Front Immunol; 2020; 11():603312. PubMed ID: 33329598
[TBL] [Abstract][Full Text] [Related]
50. Agents against cytokine synthesis or receptors.
Yamagata T; Ichinose M
Eur J Pharmacol; 2006 Mar; 533(1-3):289-301. PubMed ID: 16457805
[TBL] [Abstract][Full Text] [Related]
51. Revisiting Type 2-high and Type 2-low airway inflammation in asthma: current knowledge and therapeutic implications.
Robinson D; Humbert M; Buhl R; Cruz AA; Inoue H; Korom S; Hanania NA; Nair P
Clin Exp Allergy; 2017 Feb; 47(2):161-175. PubMed ID: 28036144
[TBL] [Abstract][Full Text] [Related]
52. Reassessing the Th2 cytokine basis of asthma.
O'Byrne PM; Inman MD; Adelroth E
Trends Pharmacol Sci; 2004 May; 25(5):244-8. PubMed ID: 15120489
[TBL] [Abstract][Full Text] [Related]
53. Pharmacokinetic/pharmacodynamic profile of reslizumab in asthma.
Matera MG; Rogliani P; Calzetta L; Cazzola M
Expert Opin Drug Metab Toxicol; 2018 Feb; 14(2):239-245. PubMed ID: 29268638
[TBL] [Abstract][Full Text] [Related]
54. Therapeutic effects of anti-B7-H3 antibody in an ovalbumin-induced mouse asthma model.
Chen ZR; Zhang GB; Wang YQ; Yan YD; Zhou WF; Zhu C; Chen Y; Wang J; Ji W
Ann Allergy Asthma Immunol; 2013 Oct; 111(4):276-81. PubMed ID: 24054363
[TBL] [Abstract][Full Text] [Related]
55. Increased serum IL-17A and Th2 cytokine levels in patients with severe uncontrolled asthma.
Hasegawa T; Uga H; Mori A; Kurata H
Eur Cytokine Netw; 2017 Mar; 28(1):8-18. PubMed ID: 28840844
[TBL] [Abstract][Full Text] [Related]
56. Pharmacokinetics and pharmacodynamics of monoclonal antibodies for asthma treatment.
Bagnasco D; Heffler E; Testino E; Passalacqua G; Canonica GW
Expert Opin Drug Metab Toxicol; 2019 Feb; 15(2):113-120. PubMed ID: 30632416
[TBL] [Abstract][Full Text] [Related]
57. [Dupilumab : a new treatment for severe T2 high asthma].
Louis R; Sabbe M; Bougard N; Frix AN; Schleich F
Rev Med Liege; 2024 Apr; 79(4):255-259. PubMed ID: 38602214
[TBL] [Abstract][Full Text] [Related]
58. Modeling T
Foster PS; Maltby S; Rosenberg HF; Tay HL; Hogan SP; Collison AM; Yang M; Kaiko GE; Hansbro PM; Kumar RK; Mattes J
Immunol Rev; 2017 Jul; 278(1):20-40. PubMed ID: 28658543
[TBL] [Abstract][Full Text] [Related]
59. Dupilumab for the treatment of asthma.
Pelaia C; Vatrella A; Gallelli L; Terracciano R; Navalesi P; Maselli R; Pelaia G
Expert Opin Biol Ther; 2017 Dec; 17(12):1565-1572. PubMed ID: 28990423
[TBL] [Abstract][Full Text] [Related]
60. Meta-analysis of randomized controlled trials for the efficacy and safety of anti-interleukin-13 therapy with lebrikizumab in patients with uncontrolled asthma.
Liu Y; Zhang S; Chen R; Wei J; Guan G; Zhou M; Dong N; Cao Y
Allergy Asthma Proc; 2018 Sep; 39(5):332-337. PubMed ID: 30153886
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
